Trade RGNX anytime, even after market hours
Regulated by
MAS
Trusted by
400,000+ users
REGENXBIO Inc. (RGNX) is trading at US$9.46, up 0.97% today as of Aug 28, 13:01 EDT. The company has a market capitalisation of US$707.66M. Over the past 52 weeks, RGNX has traded between US$5.46 and US$16.19. On Syfe you can trade RGNX with $0 commission and add it to your watchlist.
| Previous close | US$9.37 |
|---|---|
| Market cap | US$707.66M |
| 52-week range | US$5.46 – US$16.19 |
| Volume | 873.79K |
| Exchange | US |
Add to Watchlist
Set Price Alert
REGENXBIO Inc.
REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.
Year: 2015
REGENXBIO Inc. (RGNX) stock is trading at US$9.46, +0.97% from the previous close of US$9.37.
The market cap for REGENXBIO Inc. (RGNX) stock is approximately US$707.66M.
The 52-week high for REGENXBIO Inc. (RGNX) stock is US$16.19.
The 52-week low for REGENXBIO Inc. (RGNX) stock is US$5.46.
REGENXBIO Inc. (RGNX) does not currently pay a dividend.
Stay on top of RGNX
Price moves, news and earnings — straight to your inbox.
Est. order value
US$0.00
Snapshot
